Contemporary use of lipid-lowering therapy for secondary prevention in Korean patients with atherosclerotic cardiovascular diseases
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: We evaluated the contemporary use of lipid-lowering therapy (LLT) in Korean patients with atherosclerotic cardiovascular disease (ASCVD), and identified factors associated with statin non-prescription. Methods: Using the Korean Health Insurance Review and Assessment data, we identified LLT-naïve subjects newly diagnosed with ASCVD between 2011 and 2012, and followed up until 2015. LLT-naïve status was defined as no LLT prescription for 1 year before ASCVD diagnosis. ASCVD was defined as first hospitalization or emergency room visit for coronary artery disease (CAD), acute cerebrovascular disease (CVD), or peripheral artery disease (PAD). Statin intensity was defined per the 2013 American College of Cardiology/American Heart Association guideline for cholesterol treatment. Results: The study enrolled 80,884 subjects newly diagnosed with ASCVD, of whom only 48,725 (60.2%) received LLT during the follow-up period. Statin, combination of statin and non-statin, and non-statin LLT were administered in 50.5%, 9.7%, and 0.1% of all subjects, respectively. Statins were prescribed to 80.4% of CAD patients but only to 50.2% and 46.8% of CVD and PAD patients. Statin-based LLT usually had moderate- (77.2%) or high-intensity (18.5%). Subjects not prescribed statins were younger or older (< 40 or ≥ 70 years), more commonly female, and more likely to have comorbidities. Statins were prescribed at the time of ASCVD diagnosis in 45.5% of all subjects, and in 53.0% within 90 days of diagnosis. Conclusions: Only 60% of LLT-naïve Korean patients newly diagnosed with ASCVD received statins. Statins were often prescribed in subjects with CAD but less commonly in those with CVD or PAD. Moderate-intensity statins were most frequently used.
Abstract
Background/Aims: We evaluated the contemporary use of lipid-lowering therapy (LLT) in Korean patients with atherosclerotic cardiovascular disease (ASCVD), and identified factors associated with statin non-prescription. Methods: Using the Korean Health Insurance Review and Assessment data, we identified LLT-naïve subjects newly diagnosed with ASCVD between 2011 and 2012, and followed up until 2015. LLT-naïve status was defined as no LLT prescription for 1 year before ASCVD diagnosis. ASCVD was defined as first hospitalization or emergency room visit for coronary artery disease (CAD), acute cerebrovascular disease (CVD), or peripheral artery disease (PAD). Statin intensity was defined per the 2013 American College of Cardiology/American Heart Association guideline for cholesterol treatment. Results: The study enrolled 80,884 subjects newly diagnosed with ASCVD, of whom only 48,725 (60.2%) received LLT during the follow-up period. Statin, combination of statin and non-statin, and non-statin LLT were administered in 50.5%, 9.7%, and 0.1% of all subjects, respectively. Statins were prescribed to 80.4% of CAD patients but only to 50.2% and 46.8% of CVD and PAD patients. Statin-based LLT usually had moderate- (77.2%) or high-intensity (18.5%). Subjects not prescribed statins were younger or older (< 40 or ≥ 70 years), more commonly female, and more likely to have comorbidities. Statins were prescribed at the time of ASCVD diagnosis in 45.5% of all subjects, and in 53.0% within 90 days of diagnosis. Conclusions: Only 60% of LLT-naïve Korean patients newly diagnosed with ASCVD received statins. Statins were often prescribed in subjects with CAD but less commonly in those with CVD or PAD. Moderate-intensity statins were most frequently used.
참고문헌 (33)
- Roth GA, "Global and regional patterns in cardiovascular mortality from 1990 to 2013", Circulation, 132, pp.1667~1678 (2015)
- Committee for the Korean Guidelines for the Management of Dyslipidemia, "2015 Korean Guidelines for the Management of Dyslipidemia: Executive Summary (English Translation)", Korean Circulation Journal, 46(3), pp.275~306 (2016), 대한심장학회[DOI]
- "Korea National Health and Nutrition Examination Survey" (2013)[URL]
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, "Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)", JAMA, 285, pp.2486~2497 (2001)
- Grundy SM, "Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines", Circulation, 110, pp.227~239 (2004)
- Stone NJ, "2013 ACC", AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults : a report of the American College of Cardiology, J Am Coll Cardiol, pp.2014, 63[DOI]
- European Association for Cardiovascular Prevention & Rehabilitation, "ESC", EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), 2011, pp.32, 1769~1818
- Catapano AL, "2016 ESC", EAS guidelines for the management of dyslipidaemias, 2016, pp.37, 2999~3058
- Choi NK, "Signal detection of rosuvastatin compared to other statins : data-mining study using national health insurance claims database", Pharmacoepidemiol Drug Saf, 19, pp.238~246 (2010)
- Koo BK, "The incidence and prevalence of diabetes mellitus and related atherosclerotic complications in Korea : a National Health Insurance Database Study", PLoS One, 9, pp.e110650~ (2014)
- Hirsch AT, "National health care costs of peripheral arterial disease in the medicare population", Vasc Med, 13, pp.209~215 (2008)
- Subherwal S, "Missed opportunities : despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains", Circulation, 126, pp.1345~1354 (2012)
- Lee SR, "Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants : a nationwide population-based study", PLoS One, 12, pp.e0189495~ (2017)
- National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III), "Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report", Circulation, 106, pp.3143~3421 (2002)
- Kernan WN, "Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack : a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2014, pp.45, 2160~2236
- Virani SS, "Is high-intensity statin therapy associated with lower statin adherence compared with lowto moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology", American Heart Association Cholesterol Management Guidelines, 2014, pp.37, 653~659
- Virani SS, "Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease", Am Heart J, 162, pp.725~732 (2011)
- Lee JH, "Contemporary trends of optimal evidence-based medical therapy at discharge for patients surviving acute myocardial infarction from the Korea acute myocardial infarction registry", Clin Cardiol, 38, pp.350~356 (2015)
- Lee CH, "Impact of statin usage patterns on outcomes after percutaneous coronary intervention in acute myocardial infarction : Korea Working Group on Myocardial Infarction registry(KorMI)study", J Geriatr Cardiol, 11, pp.93~99 (2014)
- Cannon CP, "Intensive versus moderate lipid lowering with statins after acute coronary syndromes", N Engl J Med, 350, pp.1495~1504 (2004)
- LaRosa JC, "Intensive lipid lowering with atorvastatin in patients with stable coronary disease", N Engl J Med, 352, pp.1425~1435 (2005)
- Kim M, "Comparing high-intensity versus low-to moderate-intensity statin therapy in Korean patients with acute myocardial infarction", J Lipid Atheroscler, 3, pp.97~104 (2014)
- Kim J, "Effects of statin intensity and adherence on the long-term prognosis after acute ischemic stroke", Stroke, 48, pp.2723~2730 (2017)
- Im E, "High-intensity statin treatments in clinically stable patients on aspirin monotherapy 12 months after drug-eluting stent implantation: a randomized study", Rev Esp Cardiol (Engl Ed), 71, pp.423~431 (2018)
- Rodriguez F, "Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease", JAMA Cardiol, 2, pp.47~54 (2017)
- Garcia M, "Cardiovascular disease in women : clinical perspectives", Circ Res, 118, pp.1273~1293 (2016)
- "High-dose atorvastatin after stroke or transient ischemic attack", N Engl J Med, 378, pp.2450~ (2018)
- Kjekshus J, "Rosuvastatin in older patients with systolic heart failure", N Engl J Med, 357, pp.2248~2261 (2007)
- Tavazzi L, "Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial", Lancet, 372, pp.1231~1239 (2008)
- Oikawa T, "Prognostic impact of statin intensity in heart failure patients with ischemic heart disease: a report from the CHART-2 (Chronic Heart Failure Registry and Analysis in the Tohoku District 2)Study", J Am Heart Assoc, 7, pp.e007524~ (2018)
- Harper CR, "Managing dyslipidemia in chronic kidney disease", J Am Coll Cardiol, 51, pp.2375~2384 (2008)
- Wanner C, "KDIGO clinical practice guideline for lipid management in CKD : summary of recommendation statements and clinical approach to the patient", Kidney Int, 85, pp.1303~1309 (2014)
- Teramoto T, "Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan: 2012 version", J Atheroscler Thromb, 20, pp.517~523 (2013)